EZH2 and Miyoshi myopathy: The redistribution of histone marks and changes in the DNA methylome, along with the physical interaction between the catalytic subunit of PRC2, EZH2 and DNMT1 supports the rationale for a therapeutic strategy of combining EZH2 and DNMTs inhibition as a potential clinical approach in MM.